Explanipedia

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade Open

Adam Grippin, Christiano Marconi, Sage Copling, Nan Li, Chen Braun , et al. · 2025

Immune checkpoint inhibitors (ICIs) extend survival in many patients with cancer but are ineffective in patients without pre-existing immunity^1-9. Although personalized mRNA cancer vaccines sensitize tumours to ICIs by directing…

Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report Open

Jillian R. Gunther, Joanna C. Yang, Carla Hajj, Andrea K. Ng, J.L. Brady , et al. · 2025

Treatment of hematologic malignancies patients with hRT was generally well tolerated with few unexpected toxicities. These data provide guidance for emergencies, and hRT may be useful and could be considered even in routine settings, espec…

Publication Disparity in Lymphomatous Hematologic Radiation Oncology Open

Omran Saifi, Mohamad El-Jammal, Jennifer Peterson, Jillian R Gunther, Chelsea C. Pinnix , et al. · 2025

A Robust Radiotherapy Continuity System that Enables Patient Treatments during a Cybersecurity Event Open

Christopher Nelson, Miriam Olivares, Bouthaina S. Dabaja, Khôi Nguyen, Peter Balter · 2025

Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study Open

Nikhil Yegya‐Raman, John P. Plastaras, Christopher M. Wright, Monica Chelius, Siqi Zhang , et al. · 2025

Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refr…

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas Open

Gohar Manzar, Chelsea C. Pinnix, Stephanie O. Dudzinski, Kathryn E. Marqueen, E. Elaine , et al. · 2025

Background Select patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment …

Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024 Open

Belinda A. Campbell, H. Miles Prince, Karin Thursky, Bouthaina S. Dabaja, Richard T. Hoppe , et al. · 2024

Cutaneous T-cell lymphomas (CTCL) are a rare collection of diseases, frequently associated with diagnostic challenges and complex management dilemmas. The multidisciplinary team is vital for accurate clinico-pathological diagnoses and for …

Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation? Open

Penny Fang, Sonal S. Noticewala, Susan Wu, Jillian R. Gunther, Ethan B. Ludmir , et al. · 2024

In this Western Hemisphere cohort of early-stage ENKTCL patients treated with CMT, ENI may have a potential clinical benefit, particularly in patients who are treated with non-asparaginase-containing CMT, such as in patients treated with r…

Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung Open

Susan Wu, Penny Fang, Ahmed Fetooh, Gohar Manzar, Kelsey L. Corrigan , et al. · 2024

Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma Open

Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunther, Penny Fang, Susan Wu , et al. · 2024

Importance Radiation therapy to doses of 24 to 36 Gy is currently used to treat indolent B-cell lymphoma of the ocular adnexa; however, ocular adverse effects are common. Objective To determine if a response-adapted radiation therapy strat…

Motion Management: The Road Map to Accurate Radiation Treatment Delivery Open

Bouthaina S. Dabaja, Susan Wu, Nicholas J. Short · 2024

Radiation therapy is a key contributor to positive outcomes in hematological malignancies. However, this is contingent on minimizing the exposure of critical normal organs. The introduction of computed tomography (CT) for radiation treatme…

Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Leukemia Open

Berthold Schrank, Gohar Manzar, Susan Wu, Jillian R. Gunther, Penny Fang , et al. · 2023

Characterization of Lymphopenia during Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Patients with Aggressive B Cell Lymphomas Open

Gohar Manzar, Susan Wu, Stephanie O. Dudzinski, Michael K. Rooney, Andrew Jallouk , et al. · 2023

Outcomes and Toxicities in Patients with Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract Open

Erin Cha, Gohar Manzar, Kelsey L. Corrigan, Alison Yoder, Berthold Schrank , et al. · 2023

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma Open

Raphaël Steiner, Steven R. Hwang, Arushi Khurana, Thomas M. Habermann, Narendranath Epperla , et al. · 2023

In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). …

Radiation for hematologic malignancies: from cell killing to immune cell priming Open

Bouthaina S. Dabaja, Michael T. Spiotto · 2023

Over the past half-century, the role of radiotherapy has been revolutionized, in part, by a shift from intent to directly kill cancer cells to the goal of priming anti-tumor immune responses that attack both irradiated and non-irradiated t…

Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report Open

Joanna C. Yang, Jillian R. Gunther, Carla Hajj, Andrea K. Ng, J. L. Brady , et al. · 2023

Purpose/Objectives: During COVID19, shorter radiation therapy (RT) courses were considered to minimize patient exposure, ensure staff safety, and conserve healthcare resources. Due to concerns with the safety of systemic therapy, RT demand…

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia Open

Hagop M. Kantarjian, Fadi G. Haddad, Nitin Jain, Koji Sasaki, Nicholas J. Short , et al. · 2023

Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma Open

Siba El Hussein, L. Jeffrey Medeiros, Kirill A. Lyapichev, Hong Fang, Fatima Zahra Jelloul , et al. · 2023

Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19 Open

Dereddi Raja Reddy, John Cuenca, Joshua Botdorf, Mayoora Muthu, Ankit Hanmandlu , et al. · 2022

Central Nervous System Prophylaxis and Treatment in Acute Leukemias Open

Susan Wu, Nicholas J. Short, Lewis Nasr, Bouthaina S. Dabaja, Penny Fang · 2022

Opinion statement Improvements in systemic therapy in the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have improved patient outcomes and reduced the incidence of CNS relapse. However, management of pati…

Survival Outcomes of Patients with Mycosis Fungoides Involving the External Ear and Ear Canal Open

Alex J. Wilkinson, Marc‐Elie Nader, Dianna Roberts, Madeleine Duvic, Jillian R. Gunther , et al. · 2022

Objectives/Hypothesis Mycosis Fungoides (MF) is the most common subtype of cutaneous T‐cell lymphoma. Disease involvement of specific locations may be more significant than simply the symptoms associated with that site; it is possible that…

Second malignancies in patients with Hodgkin’s Lymphoma: Half a century of experience Open

Bouthaina S. Dabaja, David Boyce-Fappiano, Wenli Dong, Ethan P. Damron, Penny Fang , et al. · 2022

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022 Open

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand , et al. · 2022

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment opt…

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement Open

Serkan Akın, Chitra Hosing, Issa F. Khouri, Sairah Ahmed, Amin M. Alousi , et al. · 2022

Secondary central nervous system large B-cell lymphoma (SCNSL) is rare, with a generally poor prognosis. There is limited data about the role of autologous stem cell transplantation (ASCT) in these high-risk patients. We explored in this s…

Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or Without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia Open

Hagop M. Kantarjian, Nitin Jain, Koji Sasaki, Elias Jabbour, Fadi G. Haddad , et al. · 2022

Radiation Therapy can be Safely Incorporated Into Pre-Transplant Treatment Regimens for Patients With Multiple Myeloma Open

Ethan P. Damron, Muzaffar H. Qazilbash, Penny Fang, Susan Wu, Bouthaina S. Dabaja , et al. · 2021

Efficacy and Toxicity of Alternative Radiation Treatment Schemes for Patients With Hematologic Malignancies: A Collaborative ILROG COVID Era Report Open

Jillian R. Gunther, Joanna C. Yang, Carla Hajj, Andrea K. Ng, J.L. Brady , et al. · 2021

An International, Multi-Centre Study of Radiotherapy for Bilateral Indolent Orbital Adnexal Lymphomas (IOAL) Open

Krystel Tran, Richard Tsang, Chang‐Ok Suh, Hong In Yoon, Senzo Taguchi , et al. · 2021

Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report Open

Jenna M. Kahn, Joanna C. Yang, Joachim Yahalom, Bouthaina S. Dabaja, Neha Vapiwala , et al. · 2021

Bouthaina S. Dabaja YOU? Author Swipe